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Sir,
The recent article by Sasieni et al is to be welcomed in that it
supports previous evidence that 3-yearly screening may be more
effective than 5-yearly in the prevention of cervical cancer, at least in
women under 50 years of age (Sasieni et al, 2003). However, the
conclusions about the effectiveness of screening in different age
groups are not entirely justified from the data collected. For instance,
comparison of cervical smear histories in women with and without
cancer becomes less useful as a measure of screening effectiveness
when screening coverage is high in the population at risk, and when
the number of cancers that are screen-detected is not known.
The data and conclusions may be questioned for the following
reasons. The screening histories cover different periods of
time, some going back to the late 1980s, and do not account
for significant changes in practice and quality control that
have taken place since the 1990s. The screening histories in the
control group are not what would be expected from a normal
population. In Table 6 (Sasieni et al, 2003), 18.4% had never
had a smear, whereas in England only 7% were recorded as
having ‘no record’ of a test even as early as 1994–95 (Department
of Health, 2001). The percentage of cancer cases with no record
of a test is not given for comparison, because Table 6 includes
recent symptomatic and diagnostic tests taken within 6 months.
Cases in which the stage of cancer was unknown have been
excluded, although these would almost certainly have represented
fully invasive rather than microinvasive cancers. Women whose
latest negative smear was reported 3 or 5 years before diagnosis
were assumed to have been screened 3- or 5-yearly, when no
information was provided about their previous screening history.
It is not only the interval since the latest test that counts, but
also the number of rounds of screening a woman has experienced
during the years in which CIN might have been detected.
Extending the interval to 5-yearly in women over 50 is probably
only justified in women who have been screened regularly before
that age.
It is misleading to conclude that screening is less effective at
preventing frankly invasive cancer in women under 40 when its
mechanism lies in the treatment of high-grade cervical intrae-
pithelial neoplasia (CIN). In 1998, 90% of cases of CIN3 were
detected in women aged less than 45 and approximately 70% in
women aged less than 35. More than 4000 cases of CIN3 (15% of all
cases) were detected in women under 25 (Cancer Research UK,
2003). How many of those women would develop cancer if they
were left untreated? In how many would the CIN3 become so
extensive that it would be difficult to excise, which is often the case
by the time microinvasive cancer develops?
If the aim of cervical screening is to detect pre-cancer, the
relative risk suggesting that screening has little effect in preventing
cancer in young women is irrelevant. Invasive cancer in young
women is rare and nowadays most of the cases are screen-detected.
These include microinvasive cancers, which have been excluded by
Sasieni et al. In the 12-year study of cancers in Southampton
between 1985 and 1996, referred to by Sasieni et al, there was a
reversal of the ratio of symptomatic: screen-detected cancers in
women aged 25–34 years from 10:4 in 1985–87 to 4:8 in 1994–
96, but no fall in the numbers of cancers in that age group (Herbert
et al, 2001). This is a clinically important benefit of screening
young women because 90% of screen-detected cancers were
diagnosed at stage I, giving an excellent prognosis with respect
to life expectancy (Herbert et al, 2001).
I can see no evidence from this study to suggest that women
aged 20–24 should not be screened, bearing in mind that not all
women would be screened as soon as they were 25. Treatment of
high-grade CIN in young women reduces the risk of symptomatic
cancer presenting later in life, after an interval that is unpredic-
table for an individual woman.
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